Domenica Ghanem

4-5-18

At a recent rally in New Hampshire, Donald Trump called for the death penalty for drug traffickers as part of a plan to combat the opioid epidemic in the United States. At a Pennsylvania rally a few weeks earlier, he called for the same.

Now his administration is taking steps toward making this proposal a reality. Attorney General Jeff Sessions issued a memo on March 21 asking prosecutors to pursue capital punishment for drug traffickers — a power he has thanks to legislation passed under President Bill Clinton.

Time and again, these punitive policies have proven ineffective at curbing drug deaths. That’s partly because amping up the risk factor for traffickers makes the trade all that more lucrative, encouraging more trafficking, not less.

But it’s also because these policies don’t address the true criminals of the opioid crisis: Big Pharma.

The president knows this, in a way. These companies “contribute massive amounts of money to political people,” he said at a press conference in October 2017 — even calling out Mitch McConnell, who was standing beside him, for taking that money. Pharmaceutical manufacturers were “getting away with murder,” Trump complained in the same speech.

The pharmaceutical industry spends more than any other industry on influencing politicians, with two lobbyists for every member of Congress.

For once, he’s wasn’t wrong.

The pharmaceutical industry spends more than any other industry on influencing politicians, with two lobbyists for every member of Congress. Nine out of ten House members and all but three senators have taken campaign contributions from Big Pharma.

Opioid pioneer Purdue Pharma, the creator of OxyContin, bankrolled a campaign to change the prescription habits of doctors who were wary of the substance’s addictive properties, going so far as to send doctors on all-expense-paid trips to pain-management seminars. The family that started it all is worth some $13 billion today.

Meanwhile, five companies contributed more than $9 million to interest groups for things like promoting their painkillers for chronic pain and lobbying to defeat state limits on prescribing opioids.

Insys Therapeutics, a company whose founder was indicted for allegedly bribing doctors to write prescriptions for fentanyl (a substance 50 times stronger than heroin), spent $500,000 to stop marijuana legalization in Arizona in 2016.

These companies don’t stop at promoting opioids. They also spend big on stopping legislation that would actually help curb opioid use.

Insys Therapeutics, a company whose founder was indicted for allegedly bribing doctors to write prescriptions for fentanyl (a substance 50 times stronger than heroin), spent $500,000 to stop marijuana legalization in Arizona in 2016.

In response, cities and states from New York City to Ohio are suing pharmaceutical companies for their role in the deaths of tens of thousands of Americans every year. It’s time for the federal government to get behind them.

Of course, going after these companies isn’t going to eliminate opioid abuse on its own. That will take combating the root social and economic causes that lead to so many deaths of despair.

But it’s clear who the real profiteers of the opioid epidemic are. If Trump wanted to get real about curbing incentives for selling opioids, he’d turn away from street dealers and target the real opioid-producing industry.